Condition (MeSH)
Hirsutism
ClinicalTrials.gov lists 40 trials for Hirsutism or a narrower condition beneath it. Corcept Therapeutics has the most among industry and government lead sponsors, with 3.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
40 of the 40 trials are tagged with Hirsutism itself; the rest are tagged with a narrower condition beneath it.
When did Hirsutism trials start? (21)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 3
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2025 | 1 |
| 2024 | 3 |
| 2023 | 3 |
| 2022 | 1 |
| 2021 | 1 |
| 2020 | 2 |
| 2017 | 1 |
| 2016 | 2 |
| 2015 | 1 |
Showing 10 of 21 earlier years.
No forecast is made for this condition: it averages 2.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Hirsutism trials in? (8)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 3 |
| Phase 1/2 | 2 |
| Phase 2 | 2 |
| Phase 2/3 | 1 |
| Phase 3 | 2 |
| Phase 4 | 5 |
| Not applicable | 11 |
| Observational | 14 |
How many Hirsutism trials are recruiting? (5)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 6 |
| Completed | 19 |
| Suspended | 1 |
| Terminated | 4 |
| Unknown status | 10 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Hirsutism trials? (7)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Corcept Therapeutics | 3 |
| Sandoz | 2 |
| Scilex Ltd. | 2 |
| Alexander Shayesteh | 1 |
| Allergan | 1 |
Showing 5 of 7 sponsors.
Which drugs are being tested for Hirsutism? (2)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Mifepristone | 2 |
| Eflornithine | 2 |
Interventions as named in the registry (13)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Bicalutamide 50 mg Film-Coated Tablets (Casodex) (Astrazeneca Pharmaceutical LP, USA) | 2 |
| 1% Metformin | 2 |
| triglycerides (Intralipid 20%) | 1 |
| myo-inositol 2000 gr + folic acid 200 mcg | 1 |
| GLIDE | 1 |
Showing 5 of 13 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Hirsutism trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Blood Postassium Decreased | 4 | 1 |
| Adrenal Insufficiency | 3 | 2 |
| Respiratory Failure | 3 | 2 |
| Dyspnoea | 2 | 2 |
| Pneumonia | 2 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Hirsutism? (103)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Androgens and hirsutism score of overweight women with polycystic ovary syndrome improved after vitamin D treatment: A randomized placebo controlled clinical trial. | Clinical nutrition (Edinburgh, Scotland) | 2021 | Yes |
| The role of androgen receptor CAG repeat polymorphism in androgen excess disorder and idiopathic hirsutism. | Journal of endocrinological investigation | 2020 | Yes |
| Psychological distress, anger and quality of life in polycystic ovary syndrome: associations with biochemical, phenotypical andsocio-demographic factors. | Journal of psychosomatic obstetrics and gynaecology | 2018 | Yes |
| Evaluation and Treatment of Hirsutism in Premenopausal Women: An Endocrine Society Clinical Practice Guideline. | The Journal of clinical endocrinology and metabolism | 2018 | Yes |
| Treatment Options for Hirsutism: A Systematic Review and Network Meta-Analysis. | The Journal of clinical endocrinology and metabolism | 2018 | Yes |
Showing 5 of 103 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.